Next Article in Journal
Urine Sodium Excretion in Children with Primary Hypertension: A Single-Center Retrospective Study
Previous Article in Journal
Evaluating Techniques for Vertical Ridge Augmentation via Comparative Study of Clinical Outcomes: A Systematic Review
Previous Article in Special Issue
Management of Myeloproliferative Neoplasms: An Integrative Approach
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 14
Issue 24
10.3390/jcm14248641
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Case Report

Regression of Post-Essential Thrombocythaemia Myelofibrosis with Intermittent Hydroxyurea Therapy: A Case Report

by
Arumugam Manoharan
1,* and
Ian Tang
2
1
Southern Sydney Haematology, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong NSW 2500, Australia
2
Douglas Hanley Moir Pathology, Sydney, NSW 2093, Australia
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2025, 14(24), 8641; https://doi.org/10.3390/jcm14248641 (registering DOI)
Submission received: 12 October 2025 / Revised: 18 November 2025 / Accepted: 3 December 2025 / Published: 5 December 2025
(This article belongs to the Special Issue Myeloproliferative Neoplasms (MPN): Recent Advances, Current Practices and Future Perspectives)
Versions Notes

Abstract

We describe a patient with post-essential thrombocythaemia myelofibrosis treated with intermittent hydroxyurea (Hu) therapy (20 mg/Kg, given as a single dose, thrice weekly), achieving sustained disease control and regression of bone marrow fibrosis. Additionally, we discuss the efficacy of and rationale for use of intermittent Hu therapy in patients with myeloproliferative neoplasms, including those deemed to be Hu-resistant or intolerant to the commonly used continuous therapy.
Keywords: essential thrombocythaemia; myelofibrosis; intermittent hydroxyurea therapy; fibrosis regression essential thrombocythaemia; myelofibrosis; intermittent hydroxyurea therapy; fibrosis regression

Share and Cite

MDPI and ACS Style

Manoharan, A.; Tang, I. Regression of Post-Essential Thrombocythaemia Myelofibrosis with Intermittent Hydroxyurea Therapy: A Case Report. J. Clin. Med. 2025, 14, 8641. https://doi.org/10.3390/jcm14248641

AMA Style

Manoharan A, Tang I. Regression of Post-Essential Thrombocythaemia Myelofibrosis with Intermittent Hydroxyurea Therapy: A Case Report. Journal of Clinical Medicine. 2025; 14(24):8641. https://doi.org/10.3390/jcm14248641

Chicago/Turabian Style

Manoharan, Arumugam, and Ian Tang. 2025. "Regression of Post-Essential Thrombocythaemia Myelofibrosis with Intermittent Hydroxyurea Therapy: A Case Report" Journal of Clinical Medicine 14, no. 24: 8641. https://doi.org/10.3390/jcm14248641

APA Style

Manoharan, A., & Tang, I. (2025). Regression of Post-Essential Thrombocythaemia Myelofibrosis with Intermittent Hydroxyurea Therapy: A Case Report. Journal of Clinical Medicine, 14(24), 8641. https://doi.org/10.3390/jcm14248641

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop